The primary aim of this study is to investigate the safety and tolerabilty of AZD4017 when given as single oral ascending doses to healthy volunters. This will be done by comparing the effect of AZD4017 to placebo. The study will aslo investigate the absorption, distrubution and disappearance of AZD4017 in the body. Information about plasma concentrations of AZD4017 vs time after dose intake will also be collected. The future indication for AZD4017 is planned to be Type 2 Diabetes Mellitus.

Inclusion Criteria:

• Provision of signed written and dated informed consent
• BMI between 19 and 30 kg/m2
• Subjects must be willing to use barrier methods of contraception

Exclusion Criteria:

• History of any clinical significant disease
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product
• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• Laboratory blood sample result showing elevated liverenzymes (ASAT, ALAT) and muscle enzymes (CK).